Abstract
Level of adherence to tobacco cessation medication regimens is believed to be causally related to medication effectiveness. This study aimed to evaluate the efficacy of varenicline directly observed therapy (DOT) on varenicline adherence and smoking cessation rates among smokers with opioid use disorder (OUD) receiving methadone treatment. Multicenter, parallel-group two-arm randomized controlled trial. Urban opioid treatment program (OTP) in the Bronx, New York, USA. Daily smokers of ≥5 cigarettes/day, interested in quitting (ladder of change score 6-8), in methadone treatment for ≥3months, attending OTP≥3days/week. Participants' mean age was 49years, 56% were male, 44% Latino, 30% Black, and they smoked a median of 10 cigarettes/day. Individual, block, random assignment to 12weeks of varenicline, either directly observed with methadone (DOT, n=50) or via unsupervised self-administered treatment (SAT, n=50). The primary outcome was adherence measured by pill count. The secondary outcome was 7-day point prevalence tobacco abstinence verified by expired carbon monoxide (CO)<8 parts per million. Retention at 24weeks was 92%. Mean adherence was 78.5% [95% confidence interval (CI)=71.8-85.2%] in the DOT group versus 61.8% in the SAT group (95% CI=55.0-68.6%); differences were driven by DOT effects in the first 6weeks. CO-verified abstinence did not differ between groups during the intervention (P=0.26), but was higher in the DOT than the SAT group at intervention end (DOT=18% versus SAT=10%, difference=8%, 95% CI=-13, 28); this difference was not significant (P=0.39) and was not sustained at 24-week follow-up. Among daily smokers attending opioid treatment programs, opioid treatment program-based varenicline directly observed therapy was associated with early increases in varenicline adherence compared with self-administered treatment, but findings were inconclusive as to whether directly observed therapy was associated with a difference in tobacco abstinence.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.